Surgery and Imatinib for Advanced Duodenal GIST
Author Information
Author(s): Mohiuddin Kamran, Nizami Saira, Munir Asma, Memon Breda, Memon Muhammed A
Primary Institution: Aga Khan University Hospital, Karachi, Pakistan
Hypothesis
Can surgery combined with imatinib improve outcomes for patients with advanced duodenal GIST?
Conclusion
Treatment with imatinib has dramatically improved the outlook for patients with advanced, unresectable and/or metastatic disease.
Supporting Evidence
- The patient remained asymptomatic and disease-free for 42 months after treatment.
- Imatinib is a targeted therapy that has improved outcomes for patients with advanced GIST.
Takeaway
A man with a serious stomach tumor was treated with surgery and a medicine called imatinib, and he is now healthy and free of disease after 42 months.
Methodology
The patient underwent surgery followed by two years of imatinib therapy.
Limitations
The study is based on a single case report, limiting generalizability.
Participant Demographics
A 56-year-old man with a history of coronary artery bypass surgery.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website